Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Coloscopie assistée par l'intelligence artificielle dans la détection et la caractérisation des lésions colorectales

12 novembre 2026 mis à jour par: ADRIANA VAZ SAFATLE RIBEIRO, Instituto do Cancer do Estado de São Paulo

Coloscopie assistée par l'intelligence artificielle dans la détection et la caractérisation des lésions colorectales: essai clinique contrôlé randomisé

The study aims to evaluate the effectiveness of artificial intelligence-assisted colonoscopy in increasing adenoma detection rate and the accuracy in the characterization of colorectal lesions, compared to standard colonoscopy, in a randomized controlled clinical trial setting.

Aperçu de l'étude

Description détaillée

Colorectal cancer (CRC) currently shows, according to GLOBOCAN, an incidence of 19.5 individuals per 100,000 inhabitants in both sexes, being the third most common cancer in men and the second in women, representing the third leading cause of death in both men and women.

According to the GLOBOCAN registry of the World Health Organization (WHO), it is estimated that CRC is the third most common type of cancer worldwide, responsible for 10% of all newly diagnosed cancer cases, corresponding to 1,931,590 cases in 2020, preceded only by lung cancer (11.4%) and breast cancer (11.7%). CRC is the second leading cause of cancer mortality (9.4%; 935,173 cases in 2020), following only lung cancer, which accounts for 18% of cancer deaths globally.

In Brazil, according to data from the National Cancer Institute (INCA), CRC mirrors the global incidence, being the second most common cancer by sex.

Colonoscopy is the most accurate CRC screening method, with sensitivity reaching 100% in the detection of colorectal lesions. According to studies, for each 1% increase in adenoma detection rate, there is a 5% decrease in CRC mortality, highlighting the importance of performing colonoscopy to detect colorectal lesions, especially adenomas.

Consequently, with the advancement of technology, new high-definition endoscopes with virtual chromoscopy and image magnification have been developed to increase adenoma detection rates. More recently, AI-assisted colonoscopy has been gaining prominence in helping prevent CRC in some medical centers worldwide, such as in Japan.

In a multicenter study with 700 patients in 2019, a significantly higher adenoma detection rate was demonstrated with AI-assisted colonoscopy compared to standard colonoscopy (54.8% vs. 40.4%). Subsequently, a randomized, double-blind clinical trial with 1,058 patients was conducted, comparing standard colonoscopy to AI-assisted colonoscopy. The result was an adenoma detection rate of 29% for AI-assisted colonoscopy and 20% for standard colonoscopy, with the difference being statistically significant. Two other studies comparing AI-assisted colonoscopy and standard colonoscopy showed similar results.

However, when analyzing the accuracy of AI systems in characterizing colorectal lesions, different results are observed in the literature. On one hand, Japanese studies report accuracies above 90% in characterizing neoplastic and non-neoplastic lesions with artificial intelligence, while other studies, such as the Dutch study and the German study, found accuracies of 74.4% and 84.7%, respectively, results significantly lower compared to the Japanese studies.

Therefore, given not only the differences in results obtained by various authors but also the differences in population and the lack of studies on AI-assisted colonoscopy in developing countries, the objective of this work is to evaluate the adenoma detection rate of AI-assisted colonoscopy and assess the accuracy of artificial intelligence in characterizing colorectal lesions.

Type d'étude

Interventionnel

Inscription (Réel)

1009

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • São Paulo
      • São Paulo, São Paulo, Brésil, 05403-010
        • Hospital das Clínicas da Faculdade de Medicina da USP

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • All patients aged 18 years or older, with an elective indication for colonoscopy who sign the informed consent form agreeing to participate in the study.

Exclusion Criteria:

  • History of inflammatory bowel disease.
  • History of colorectal cancer.
  • Personal history of colorectal surgery.
  • Contraindication to endoscopic biopsies.
  • History of intestinal polyposis syndromes.
  • Urgent or emergency cases.
  • Presence of severe, decompensated comorbidities, or with a score of 3 or higher according to the American Society of Anesthesiologists (ASA) classification.
  • Incomplete colonoscopy that does not reach the cecum.
  • Insufficient or inadequate bowel preparation, with a score lower than 6 on the Boston Bowel Preparation Scale.
  • Patients who do not agree to participate in the study and do not sign the informed consent form (ICF).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Diagnostique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Colonoscopy with the aid of artificial intelligence

Stratum 1: Patients aged 18 to 44 years

Stratum 2: Patients aged 45 to 75 years

Stratum 3: Patients aged 76 years or older

This single-center, randomized, open-label clinical trial will assess the effectiveness of artificial intelligence (AI)-assisted colonoscopy versus standard high-definition colonoscopy in detecting and characterizing colorectal lesions. Conducted over 12 months in São Paulo, Brazil, the study will include 100 adult patients undergoing elective colonoscopy.

Participants will be stratified by age and randomized (1:1) after sedation. All lesions will be resected, recorded, and analyzed histologically. The intervention group will also include AI output data (CAD EYE).

The primary goals are to evaluate adenoma detection rate (ADR) and AI diagnostic accuracy. Given the global burden of colorectal cancer (CRC), particularly in developing countries, this study aims to provide real-world data on the impact of AI in CRC screening.

Comparateur actif: Colonoscopy without the aid of artificial intelligence

Stratum 1: Patients aged 18 to 44 years

Stratum 2: Patients aged 45 to 75 years

Stratum 3: Patients aged 76 years or older

This single-center, randomized, open-label clinical trial will assess the effectiveness of artificial intelligence (AI)-assisted colonoscopy versus standard high-definition colonoscopy in detecting and characterizing colorectal lesions. Conducted over 12 months in São Paulo, Brazil, the study will include 100 adult patients undergoing elective colonoscopy.

Participants will be stratified by age and randomized (1:1) after sedation. All lesions will be resected, recorded, and analyzed histologically. The intervention group will also include AI output data (CAD EYE).

The primary goals are to evaluate adenoma detection rate (ADR) and AI diagnostic accuracy. Given the global burden of colorectal cancer (CRC), particularly in developing countries, this study aims to provide real-world data on the impact of AI in CRC screening.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of patients with at least one adenoma detected, confirmed by histopathological analysis, during colonoscopy, in the AI group vs. control group
Délai: 7 days after colonoscopy (estimated time for histopathological report release).

The measure will be expressed as the number and percentage (%) of patients with at least one adenoma detected during colonoscopy and confirmed by histopathological analysis, comparing the AI and non-AI groups (CAD EYE). Detection will be based on the analysis of biopsies performed and processed according to the standard protocol.

7 days after colonoscopy (estimated time for histopathological report release).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Diagnostic accuracy of CAD EYE for characterization of lesions as neoplastic (adenoma) or non-neoplastic (hyperplastic), compared to histopathological analysis as the gold standard.
Délai: 7 days after colonoscopy

The accuracy of artificial intelligence (CAD EYE) in characterizing detected lesions as neoplastic or non-neoplastic will be calculated, based on comparison with histopathological diagnosis (gold standard). The following will be reported: sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), in percentage (%), for each type of lesion.

7 days after colonoscopy

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 février 2025

Achèvement primaire (Réel)

30 juin 2026

Achèvement de l'étude (Réel)

24 octobre 2026

Dates d'inscription aux études

Première soumission

22 mai 2025

Première soumission répondant aux critères de contrôle qualité

4 juillet 2025

Première publication (Réel)

15 juillet 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

We do not plan to share Individual Participant Data (IPD) with other researchers due to privacy concerns and the nature of the study

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner